Regeneron Pharmaceuticals, Inc.

REGN · NASDAQ

Regeneron reported $14.34 billion of 2025 revenue and $3.61 billion of Q1 2026 revenue. The thesis turns on EYLEA franchise durability, Dupixent economics, pipeline conversion, cash generation and patent/regulatory risk.

Follow Add to Watchlist Ask Question

NASDAQ REGN Coverage Bootstrap Regeneron Pharmaceuticals, Inc.

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.